ERBB2 and breast cancer: On the other hand, the encouraging results of the tyrosine kinase inhibitor Sunitinib, when used as single agent in a phase II clinical trial on metastatic breast cancer [69], resulted in totally disappointing results in a phase III clinical trial in a HER2-negative breast cancer population both as a single agent [70] or added to chemotherapy [71].